CADL•benzinga•
Candel Therapeutics Reports Prolonged Survival In Mid-Stage Study For Pretreated Lung Cancer Patients
Summary
Candel Therapeutics' CAN-2409 extended survival in NSCLC patients, with biomarker data showing enhanced response in non-squamous cases and a strong safety profile.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on March 27, 2025 by benzinga